Evidence map›Paper›PMID 32766549›Full record

ArticleBrain communications2020

M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer's disease pathology.

Jee Hyun Yi, Daniel J Whitcomb, Se Jin Park, Celia Martinez-Perez, Saviana A Barbati, Scott J Mitchell, Kwangwook Cho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Amyloid AβInternational journal of molecular sciences · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jee Hyun YiBristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol BS1 3NY, UK.
Daniel J WhitcombBristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol BS1 3NY, UK.
Se Jin ParkDepartment of Life and Nanopharmaceutical Sciences, Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, Seoul 130-701, Korea.
Celia Martinez-PerezBristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol BS1 3NY, UK.
Saviana A BarbatiUK Dementia Research Institute at King's College London, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 9NU, UK.
Scott J MitchellUK Dementia Research Institute at King's College London, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 9NU, UK.
Kwangwook ChoBristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol BS1 3NY, UK.ORCID 0000-0001-6724-7073
King's College London · GBUniversity of Bristol · GBKyung Hee University · KR

Funding

Wellcome Trust 203249/Z/16/Z
6 · The paper itself

Abstract

Aggregation of amyloid beta and loss of cholinergic innervation in the brain are predominant components of Alzheimer's disease pathology and likely underlie cognitive impairment. Acetylcholinesterase inhibitors are one of the few treatment options for Alzheimer's disease, where levels of available acetylcholine are enhanced to counteract the cholinergic loss. However, these inhibitors show limited clinical efficacy. One potential explanation for this is a concomitant dysregulation of cholinergic receptors themselves as a consequence of the amyloid beta pathology. We tested this hypothesis by examining levels of M1 muscarinic acetylcholine receptors in the temporal cortex from seven Alzheimer's disease and seven non-disease age-matched control brain tissue samples (control: 85 ± 2.63 years old, moderate Alzheimer's disease: 84 ± 2.32 years old,

Indexed as

Alzheimer’s diseaseM1 muscarinic acetylcholine receptor (mAChR)metabotropic glutamate receptor 5 (mGluR5)recognition memory

Identifiers

PMID32766549
PMCPMC7391992
OpenAlexW3024656456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.